Immunotherapies for hepatocellular carcinoma
JM Llovet, F Castet, M Heikenwalder… - Nature reviews Clinical …, 2022 - nature.com
Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading
cause of cancer-related death and its incidence is increasing globally. Around 50% of …
cause of cancer-related death and its incidence is increasing globally. Around 50% of …
The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma
R Donne, A Lujambio - Hepatology, 2023 - journals.lww.com
The liver is the sixth most common site of primary cancer in humans and the fourth leading
cause of cancer‐related death in the world. Hepatocellular carcinoma (HCC) accounts for …
cause of cancer‐related death in the world. Hepatocellular carcinoma (HCC) accounts for …
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open …
Background No adjuvant treatment has been established for patients who remain at high
risk for hepatocellular carcinoma recurrence after curative-intent resection or ablation. We …
risk for hepatocellular carcinoma recurrence after curative-intent resection or ablation. We …
The immunological and metabolic landscape in primary and metastatic liver cancer
X Li, P Ramadori, D Pfister, M Seehawer… - Nature Reviews …, 2021 - nature.com
The liver is the sixth most common site of primary cancer in humans, and generally arises in
a background of cirrhosis and inflammation. Moreover, the liver is frequently colonized by …
a background of cirrhosis and inflammation. Moreover, the liver is frequently colonized by …
Advances in immunotherapy for hepatocellular carcinoma
B Sangro, P Sarobe, S Hervás-Stubbs… - Nature reviews …, 2021 - nature.com
Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated
by the immune system. Systemic therapy is used in the advanced stage and until 2017 …
by the immune system. Systemic therapy is used in the advanced stage and until 2017 …
[HTML][HTML] Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition)
J Zhou, H Sun, Z Wang, W Cong, J Wang, M Zeng… - Liver cancer, 2020 - karger.com
Background: Primary liver cancer, around 90% are hepatocellular carcinoma in China, is the
fourth most common malignancy and the second leading cause of tumor-related death …
fourth most common malignancy and the second leading cause of tumor-related death …
[HTML][HTML] Hepatocellular carcinoma
Liver cancer remains a global health challenge, with an estimated incidence of> 1 million
cases by 2025. Hepatocellular carcinoma (HCC) is the most common form of liver cancer …
cases by 2025. Hepatocellular carcinoma (HCC) is the most common form of liver cancer …
Neutrophils as potential therapeutic targets in hepatocellular carcinoma
The success of atezolizumab plus bevacizumab treatment contributed to a shift in systemic
therapies for hepatocellular carcinoma (HCC) towards combinations that include cancer …
therapies for hepatocellular carcinoma (HCC) towards combinations that include cancer …
NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options
In light of a global rise in obesity and type 2 diabetes, non-alcoholic fatty liver disease
(NAFLD) and non-alcoholic steatohepatitis (NASH) represent an increasingly important …
(NAFLD) and non-alcoholic steatohepatitis (NASH) represent an increasingly important …
Cell therapy: types, regulation, and clinical benefits
AEH El-Kadiry, M Rafei, R Shammaa - Frontiers in Medicine, 2021 - frontiersin.org
Cell therapy practices date back to the 19th century and continue to expand on
investigational and investment grounds. Cell therapy includes stem cell-and non–stem cell …
investigational and investment grounds. Cell therapy includes stem cell-and non–stem cell …